Workman p. Required resistance to 17-allylamino-it-demethoxygeldanamycin (17-aag, tanespimycin) in glioblastoma cells. (Cancer res (2009) 69 (1966-75))

N. Gaspar; Sy Sharp; S. Pacey; C. Jones; M. Walton; G. Vassal; S. Eccles; A. Pearson

doi:10.1158/0008-5472.CAN-69-8-COR2

Workman p. Required resistance to 17-allylamino-it-demethoxygeldanamycin (17-aag, tanespimycin) in glioblastoma cells. (Cancer res (2009) 69 (1966-75))

N. Gaspar, Sy Sharp, S. Pacey, C. Jones, M. Walton, G. Vassal, S. Eccles, A. Pearson

Résultats de recherche: Contribution à un journal › !!Comment/debate

langue originale	Anglais
Pages (de - à)	3721
Nombre de pages	1
journal	Cancer Research
Volume	69
Numéro de publication	8
Les DOIs	https://doi.org/10.1158/0008-5472.CAN-69-8-COR2
état	Publié - 15 avr. 2009

Accès au document

10.1158/0008-5472.CAN-69-8-COR2

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{af2414b789814f8bad25522f8eb38934,

title = "Workman p. Required resistance to 17-allylamino-it-demethoxygeldanamycin (17-aag, tanespimycin) in glioblastoma cells. (Cancer res (2009) 69 (1966-75))",

author = "N. Gaspar and Sy Sharp and S. Pacey and C. Jones and M. Walton and G. Vassal and S. Eccles and A. Pearson",

year = "2009",

month = apr,

day = "15",

doi = "10.1158/0008-5472.CAN-69-8-COR2",

language = "English",

volume = "69",

pages = "3721",

journal = "Cancer Research",

issn = "0008-5472",

number = "8",

}

TY - JOUR

T1 - Workman p. Required resistance to 17-allylamino-it-demethoxygeldanamycin (17-aag, tanespimycin) in glioblastoma cells. (Cancer res (2009) 69 (1966-75))

AU - Gaspar, N.

AU - Sharp, Sy

AU - Pacey, S.

AU - Jones, C.

AU - Walton, M.

AU - Vassal, G.

AU - Eccles, S.

AU - Pearson, A.

PY - 2009/4/15

Y1 - 2009/4/15

UR - http://www.scopus.com/inward/record.url?scp=65949088377&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-69-8-COR2

DO - 10.1158/0008-5472.CAN-69-8-COR2

M3 - Comment/debate

AN - SCOPUS:65949088377

SN - 0008-5472

VL - 69

SP - 3721

JO - Cancer Research

JF - Cancer Research

IS - 8

ER -